

ANGLE PLC

03:10 07 Nov 2019

ANGLE says leading European cancer centre work demonstrates Parsortix can be used as liquid biopsy for melanoma patients

ANGLE PLC (LON:AGL) (OTCMKTS:ANPCY) revealed that leading European cancer centre, University Medical Centre Hamburg-Eppendorf (UKE), Germany has published results of work demonstrating that the company's Parsortix system can be used as a liquid biopsy to investigate prediction and monitoring of therapy responses for melanoma patients.

In a statement, the AIM-listed company said the results of the study by UKE have been published in the renowned peer-reviewed medical journal, *Cancers*.

READ: ANGLE predicts FDA clearance of Parsortix in third quarter of 2020

In the research, it added, UKE used Parsortix over a five-year period, with follow-up in some cases for three years, the results showing that Parsortix can harvest circulating tumor cells (CTCs) from some melanoma patients, where other cell surface marker dependent systems are unable to do so.

ANGLE said this development holds the potential to shift current treatment options for malignant melanoma, which is the deadliest form of skin cancer, with a global incidence of 290,000 per annum and 970,000 people living with the disease, according to Globocan 2018.

Analysis of CTCs harvested from melanoma patients opens up the potential for Parsortix's use as a companion diagnostic to select appropriate therapies and regularly monitor patients with melanoma, ensuring any potential relapse is flagged early and patients can receive the best treatment possible, the group added.

The researchers demonstrated that the presence of CTCs in a patient's blood sample -where in a previous sample they had been absent - indicated relapse earlier than standard of care imaging techniques, ANGLE said.

ANGLE's founder and chief executive, Andrew Newland, commented: "As the deadliest form of skin cancer, there is a clear need for reliable biomarkers in melanoma. Initially, these can be used in drug trials where the detection of likely responders to the drug is essential and a key commercial need for pharma companies. Ultimately there is the potential for routine clinical use as a companion diagnostic in melanoma."

Price: 49.85

Market Cap: £86.14 m

1 Year Share Price Graph



October 2019 April 2020 October 2020

Share Information

Code: AGL

Listing: AIM

52 week	High	Low
	78.5	40

Sector: Pharma & Biotech

Website: www.angleplc.com

Company Synopsis:

ANGLE PLC develops products for use in rare cell diagnostics that enable early, accurate identification of an individual's condition for the prevention, treatment, and monitoring of disease.

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of ANGLE PLC named herein, including the promotion by the Company of ANGLE PLC in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).